
This study elucidates the mechanism by which high viral antigen load inhibits interferon efficacy, providing critical experimental evidence for optimizing combination immunotherapy strategies for chronic hepatitis B. It suggests that reducing antigen load must be prioritized before immune reconstitution.
Literature Overview
This article, titled "RNA interference-mediated hepatitis B virus antigen shutdown enhances the antiviral immune effects of PEGylated interferon-α via T and B cell crosstalk remodeling," published in Clinical and Molecular Hepatology, systematically explores the synergistic mechanisms and immunological basis of combining RNA interference (RNAi) with PEGylated interferon-α (PEGIFNα) for treating chronic hepatitis B (CHB). The article first highlights the current bottleneck of functional cure in CHB treatment. Subsequently, utilizing a novel humanized IFNAR mouse model, it deeply analyzes how high viral antigen load weakens the host's immune response to interferon, confirming that RNAi-mediated antigen clearance is a key prerequisite for restoring T and B cell function.Background Knowledge
Chronic hepatitis B is a major global public health challenge. Its core difficulty lies in the persistent presence of covalently closed circular DNA (cccDNA) and the immune tolerance caused by integrated HBV DNA. While nucleos(t)ide analogues (NUCs) widely used in clinical practice effectively inhibit viral replication, they struggle to clear surface antigen (HBsAg), resulting in a very low functional cure rate. Although PEGIFNα possesses both antiviral and immunomodulatory effects, patients often exhibit immune non-response or low response under high viral antigen loads. Research indicates that persistently high levels of HBsAg induce immune tolerance, suppressing the functions of CD8+ T cells and B cells, thereby hindering the reconstitution of antiviral immunity. Therefore, effectively reducing antigen load to relieve immune suppression and reactivating specific immune responses has become a critical entry point for breaking through treatment bottlenecks. This study, based on this scientific question, explores a new strategy of using RNAi technology to rapidly reduce antigen load, thereby enhancing the efficacy of interferon.
Research Methods and Core Experiments
The authors constructed a peripheral humanized IFNAR (IFNAR-hEC) mouse model capable of responding to human interferon and mimicking chronic HBV infection. The research team first established mouse models with varying viral antigen loads using different doses of AAV-HBV vectors, verifying that high HBsAg levels significantly inhibited PEGIFNα-induced IFN-γ production and T/B cell functions. Subsequently, the study employed GalNAc-conjugated HBV-specific siRNA (GalNAc-siHBV) in combination with PEGIFNα for therapeutic experiments. Using flow cytometry, ELISpot, and single-cell RNA sequencing (scRNA-seq), the team comprehensively evaluated the impact of combination therapy on the phenotype, function, and intercellular communication networks of immune cells in the liver and spleen.
Key evidence shows that the combination therapy group exhibited significant synergistic effects compared to the monotherapy group, reducing serum HBsAg levels by approximately 4 log10 IU/mL and inducing HBsAg seroclearance in about 30% of cases. scRNA-seq analysis revealed that combination therapy not only enhanced the cytotoxicity and effector functions of CD8+ T cells but also remodeled the activation status of B cells. Cell communication analysis further found that combination therapy reduced inhibitory signals between B cells (such as Cd22-Ptprc) and enhanced T-cell interactions mediated by MHC-I, as well as the interaction networks between T/B cells and between B cells and hepatocytes mediated by MHC-II.Key Conclusions and Perspectives
Research Significance and Prospects
This finding holds significant guidance for drug development, suggesting that when developing functional cure regimens, a sequential or combination strategy of "antigen reduction + immunomodulation" should be prioritized over monotherapy. For clinical monitoring, viral antigen load should serve as an important biomarker for evaluating interferon efficacy and adjusting treatment timing. Furthermore, the IFNAR-hEC mouse model and scRNA-seq analysis framework established in this study provide powerful tools for disease modeling and in-depth analysis of virus-host immune interaction mechanisms, helping to accelerate the clinical translation of novel combination therapies.
Conclusion
This study profoundly reveals the dynamic balance relationship between antigen load and immune response in the treatment of chronic hepatitis B from an immunological mechanism perspective. By confirming that RNAi-mediated antigen clearance is a prerequisite for restoring interferon efficacy, the study provides a solid scientific basis for breaking the current deadlock in achieving functional cure for CHB. From the perspective of translation from laboratory to clinic, this finding emphasizes the importance of precisely regulating viral antigen levels during the immune reconstitution process. Combination therapy successfully breaks the state of immune tolerance and induces persistent viral control by remodeling T/B cell interaction networks, particularly by enhancing MHC-mediated signal transduction. This not only provides new strategies for optimizing combinations of existing drugs but also points the way for developing auxiliary therapeutic drugs targeting specific immune checkpoints or cytokines in the future, playing a foundational role in building a more comprehensive integrated care system for chronic hepatitis B.

